Cardiovascular Systems — Q1 FY2021 Earnings Presentation
8 slides from Cardiovascular Systems's earnings presentation, Nov 4, 2020
Slide 1: Q1 FY21 Earnings Call November 4, 2020
Q1 FY21 Earnings Call November 4, 2020
Slide 2: Safe Harbor: Forward Looking Statements
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 3: Q1 Revenues of $60.5 Million, 6% Decrease
Q1 Revenues of $60.5 Million 6% Decrease ($ in millions) Revenues US Peripheral revenue declined 5% US Peripheral, US Coronary revenue US Coronary, $42.9 declined 2% $15.9 International, International decreased 42% $1.7 US Peripheral US Coronary International
Slide 4: Financial Results
Q1 FY21 Financial Results ($ in millions) Worldwide Peripheral Revenue Worldwide Coronary Revenue $45.5 $47.6 $42.6 $42.9 $20.8 $19.0 $18.5 $17.6 $30.6 6% decline $11.9 7% decline WW in Q1 WW in Q4 due to due to Covid-19 Covid-19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY2
Slide 5: Q1 FY21 vs. Q1 FY20 and Q4 FY20
Q1 FY21 vs. Q1 FY20 and Q4 FY20 $ in (000) Q1 FY21 vs. Q1 FY20 vs. Q4 FY20 Total Revenue $60,544 -6.1% 42.3% Worldwide Peripheral Revenue $42,932 -5.7% 40.0% Worldwide Coronary Revenue $17,612 -7.1% 48.4% US Revenue $58,831 -4.4% 45.4% US Peripheral Revenue $42,932 -5.2% 40.0% US Coronary Revenue $1
Slide 6: Highlights
Q1 FY21 Highlights Financial Operational - Peripheral Operational - Coronary Other Revenues -6.1% vs. LY • Peripheral franchise performed • Coronary OAS units increased • Sold 20,000 OAS units better than expected, led by an 63% compared to Q4 and were • Nearly 1,000 medical Gross Margin 79.2% 8% ye
Slide 7: Fiscal 2021 Second Quarter Guidance
Fiscal 2021 Second Quarter Guidance For the fiscal 2021 second quarter ending December 31, 2020, CSI anticipates: • Revenue of $63 million to $67 million, representing sequential revenue growth compared to the first quarter of fiscal 2021 of 4% to 11%; • Gross profit as a percentage of revenues in t
Slide 8: Investor Contact
Investor Contact: Jack Nielsen 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2020 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks
Cardiovascular Systems — Q1 FY2021 Earnings Presentation on 6ix